New hope for bone cancer patients: drug may keep sarcoma in check
NCT ID NCT04698785
First seen Feb 18, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This study tests whether the drug regorafenib, taken for up to 12 months, can help control high-grade bone sarcomas (like osteosarcoma) that didn't fully respond to standard treatment. About 36 participants aged 12 and older will receive regorafenib plus supportive care. The goal is to see if the cancer stays stable or shrinks after 4 months of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHRU Hôpital Hautepierre
RECRUITINGStrasbourg, 67098, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Georges Francois Leclerc
NOT_YET_RECRUITINGDijon, 21079, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Leon Berard
RECRUITINGLyon, 69373, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Oscar Lambret
NOT_YET_RECRUITINGLille, 59020, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu Besancon
NOT_YET_RECRUITINGBesançon, 25030, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu Saint-Etienne
NOT_YET_RECRUITINGSaint-Priest-en-Jarez, 42270, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital de La Timone
RECRUITINGMarseille, 13385, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hotel Dieu Nantes
NOT_YET_RECRUITINGNantes, 44093, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital COCHIN
RECRUITINGParis, 75014, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
ICANS
NOT_YET_RECRUITINGStrasbourg, 67200, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Icm Val D'Aurelle
NOT_YET_RECRUITINGMontpellier, 34298, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ico Rene Gauducheau
RECRUITINGSaint-Herblain, 44805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Bergonie
RECRUITINGBordeaux, 33076, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Curie
RECRUITINGParis, 75005, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Gustave Roussy
NOT_YET_RECRUITINGVillejuif, 94805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Iuct Oncopole
RECRUITINGToulouse, 31059, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.